Durvalumab: Additional Phase I/II data

Data from 42 evaluable patients with inoperable or metastatic urothelial bladder cancer in an open-label, international Phase I/II

Read the full 182 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE